首页/数据集/Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancers

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancers

NIAID Data Ecosystem2026-04-25 收录

ALK阳性肺癌

靶向治疗耐药性

数据链接：

https://www.ncbi.nlm.nih.gov/sra/SRP199720 数据链接链接失效反馈

官方服务：

资源简介：

We comprehensively analyzed autopsied samples, patient-derived cell lines, and patient-derived xenograft tumors to develop next-generation treatment strategies.

应用场景：

创建时间：

2020-06-01

前列腺癌IL-1信号通路

靶向治疗耐药性

In immunosurveillance, bone-derived immune cells infiltrate the tumor and secrete inflammatory cytokines to destroy cancer cells. However, cancer cells have evolved mechanisms to usurp inflammatory c

NIAID Data Ecosystem40

Crizotinib versus conventional chemotherapy in advanced ALK-positive lung cancer

ALK阳性肺癌

靶向药物疗效

Systematic review protocol registration

DataCite Commons2020-08-03 更新30

Genomic Characterization CS-MATCH-0007 Arm Z1A

癌症基因组数据

靶向治疗耐药性

The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA s

NIAID Data Ecosystem20

Support data_ FOXD1 Promotes Dedifferentiation and Targeted Therapy Resistance in Melanoma by Regulating the Expression of CTGF.zip

黑色素瘤

靶向治疗耐药性

In this manuscript, we show that FOXD1 is highly expressed in melanoma cells and is associated with a poor survival in patients with metastatic melanoma. FOXD1 can promote melanoma cells resistance to

NIAID Data Ecosystem30

Single-cell multi-omics reveals tumor microenvironment factors underlying poor immunotherapy responses in ALK-positive lung cancer

ALK阳性肺癌

肿瘤免疫治疗抵抗

Anaplastic lymphoma kinase (ALK) rearrangement is a major oncogenic driver in non-small cell lung cancer (NSCLC). While ALK tyrosine kinase inhibitors have shown promising therapeutic effects, overcom

NIAID Data Ecosystem20

Rapid Acquisition of Alectinib Resistance in ALK-Positive Lung Cancers

资源简介：

相关数据集